Study S003312

A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of BGM0504 Versus Placebo in Patients with Type 2 Diabetes, Inadequately Controlled with Diet and Exercise Alone

ClinicalTrials.gov record

Registration

Registration: NCT06716203
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: RECRUITING
Enrollment: 207
Start: 2024-12-02
Primary completion: 2025-12-29
Lead sponsor: BrightGene Bio-Medical Technology Co., Ltd.
Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: DRUG:Drug: 5 mg BGM0504 Administered SC; DRUG:Drug: : 10 mg BGM0504 Administered SC; DRUG:Drug: Placebo Administered SC
Results posted: FALSE

Registered primary outcomes

Change From Baseline in Hemoglobin A1c (HbA1c) [Week 0 to Week 32]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.